Tag:

China

Latest Headlines

Latest Headlines

FDA warns of contaminated Chinese meds after toddler suffers lead poisoning

The problem of contaminated cold remedies has once again surfaced in the U.S. More than seven years after diethylene glycol put authorities on high alert, a toddler in New York has suffered from lead poisoning after taking a Chinese cold remedy.

Blackstone puts $100M into Chinese orthopedic device player

Investment group Blackstone has reportedly made a $100 million investment into Chinese orthopedic device company Xinrong Best Medical Instrument Co. This is the firm's first foray into a medical investment in China, but in March it did take private Chinese tech outsourcing company Pactera Technology.

China patent will open Asia's door to Biocept's cancer Dx tests

Biocept now has what every life sciences company pursuing expansion in China needs: local patent approval.

GSK China scandal resolved with $500M fine and suspended jail sentence

Chinese justice came swift and in secret for GlaxoSmithKline today. A top executive narrowly escaped prison, and the company was convicted and will pay a fine of nearly $500 million for bribery in a country known for its corruption.

UPDATED: Merck KGaA negotiates huge production deal with Lupin

Merck is investing €80 million ($107.67 million) in a new plant in China to make treatments for diabetes and other conditions and to realize its aspirations there. But it appears it is looking to India as a way to cut production costs on some of its older products.

Feds eyed GlaxoSmithKline's Chinese consumer biz for bribery, too

GlaxoSmithKline may have a bigger problem in China than previously thought. Before news about potential corruption in its pharma business surfaced, U.S. officials were already looking into possible bribery in its consumer healthcare unit. And so was GSK.

China sweeps up gang that made and sold 90M toxic capsules

China has interrupted another group it says was illegally manufacturing capsules from chromium-laced gelatin. A lot of them.

China's new biotech billionaire beefs up cardio pipeline with $600M buyout

Newly minted biopharma billionaire Liu Dianbo has added to his fortune while burnishing his rep as one of the top biotech drug developers in China. His company, Luye Pharma Group, acquired a 58% stake in Beijing Jialin Pharma Pharmaceutical for close to $600 million, beefing up its pipeline of cardiovascular drugs while expanding its product lineup.

China's Luye Pharma founder soars into pharma's billionaire echelon

China's pharma corruption crackdown hasn't helped multinationals' top lines, which only recently began returning to normal after taking a hit last fall. But it may be opening up an opportunity for domestic drugmakers and their owners--like new Billionaire Club member Liu Dian Bo--to make a splash.

Medtronic stumbles in India, China but holds up in U.S.

Medtronic has tied its long-term growth to three pillars: strong U.S. sales, double-digit growth in emerging markets and Covidien. But last quarter, the medical device giant didn't deliver on emerging market revenue growth as it encountered difficulties with distributors in India and China. It expects to return to double-digit gains in both countries this fiscal year.